{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:27:34Z","timestamp":1789637254007,"version":"4.0.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024223","name":"Echosens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabet.2025.101709","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:21:28Z","timestamp":1760552488000},"page":"101709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management of patients with type 2 diabetes and MASLD: An overview and joint statement"],"prefix":"10.1016","volume":"51","author":[{"given":"Yasmina","family":"Chouik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence M","family":"Canivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Julla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mouillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Parlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Rouland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarra","family":"Smati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Tramunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Anty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Boursier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Carette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Castera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Garioud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Guerci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gourdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lassailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Pais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Serfaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verg\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8089-2907","authenticated-orcid":false,"given":"Cyrielle","family":"Caussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2025.101709_bib0001","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0002","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000913","article-title":"Epidemiology, screening, and co-management of type 2 diabetes and metabolic dysfunction-associated steatotic liver disease","author":"Qi","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0003","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0004","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0005","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0006","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0007","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0008","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2025.101709_bib0009","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0010","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0011","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabet.2025.101709_bib0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European liver transplant registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0013","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.cgh.2022.07.009","article-title":"Contemporary changes in etiology for hepatocellular carcinoma in liver transplantation","volume":"21","author":"Goff","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0014","doi-asserted-by":"crossref","first-page":"e0352","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.diabet.2025.101709_bib0015","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/apt.17096","article-title":"Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021","volume":"56","author":"Li","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diabet.2025.101709_bib0016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes","volume":"14","author":"Targher","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2025.101709_bib0017","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The Global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0018","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","article-title":"Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study","volume":"65","author":"Kwok","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.diabet.2025.101709_bib0019","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0020","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101272","article-title":"Management of diabetes in patients with cirrhosis: an overview and joint statement","volume":"47","author":"Boursier","year":"2021","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2025.101709_bib0022","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","volume":"165","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2025.101709_bib0023","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0024","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/liv.15171","article-title":"The burden of NAFLD in type 2 diabetic subjects from the general population: A Nationwide population-based follow-up study (NASHCO)","volume":"42","author":"Nabi","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.diabet.2025.101709_bib0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0026","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-8587(23)00329-7","article-title":"Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort","volume":"12","author":"Sch\u00f6n","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101709_bib0027","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.diabet.2025.101709_bib0028","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.diabet.2025.101709_bib0029","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.diabet.2025.101709_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2025.101709_bib0031","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.diabet.2025.101709_bib0032","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S2468-1253(23)00270-4","article-title":"Implementation of a liver health check in people with type 2 diabetes","volume":"9","author":"Abeysekera","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0033","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0034","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2025.101709_bib0035","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.diabet.2025.101709_bib0036","doi-asserted-by":"crossref","DOI":"10.2337\/dc24-2075","article-title":"Screening for metabolic dysfunction-associated steatotic liver disease-related advanced fibrosis in diabetology: a prospective multicenter study","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0037","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (masld) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0038","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2025.101709_bib0039","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2025.101709_bib0040","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabet.2025.101709_bib0042","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/oby.24033","article-title":"The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD","volume":"32","author":"Chouik","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.diabet.2025.101709_bib0043","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0044","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cgh.2022.02.059","article-title":"Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications","volume":"21","author":"Boursier","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0041","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0045","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/hep.31655","article-title":"Transient versus two-dimensional shear-wave elastography in a multistep strategy to detect advanced fibrosis in NAFLD","volume":"73","author":"Cassinotto","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0046","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.7150\/thno.40249","article-title":"Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease","volume":"10","author":"Pirmoazen","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.diabet.2025.101709_bib0047","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort\u2606","volume":"73","author":"Anstee","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0048","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-023-05894-8","article-title":"Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD). Evidence-based European recommendations for the dietary management of diabetes","volume":"66","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101709_bib0049","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/jhep.2003.50132","article-title":"Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis","volume":"37","author":"Musso","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2007.06.020","article-title":"Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study","volume":"47","author":"Zelber-Sagi","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0051","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.clnu.2023.03.021","article-title":"Practical guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN\/UEG guideline","volume":"42","author":"Bischoff","year":"2023","journal-title":"Clin Nutr"},{"key":"10.1016\/j.diabet.2025.101709_bib0052","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2025.101709_bib0053","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1097\/MEG.0000000000002158","article-title":"Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease","volume":"33","author":"Sinn","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0054","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2337\/dc17-2222","article-title":"Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose","volume":"41","author":"Galaviz","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0055","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0056","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa0804748","article-title":"Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates","volume":"360","author":"Sacks","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0057","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2337\/dc23-0602","article-title":"Prediction of cardiometabolic health through changes in plasma proteins with intentional weight loss in the DiRECT and DIADEM-I randomized clinical trials of type 2 diabetes remission","volume":"46","author":"Sattar","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0058","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0059","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41575-021-00472-y","article-title":"Dietary carbohydrates and fats in nonalcoholic fatty liver disease","volume":"18","author":"Yki-J\u00e4rvinen","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0060","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad libitum mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial","volume":"68","author":"Properzi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0061","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","article-title":"The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis","volume":"41","author":"Haigh","year":"2022","journal-title":"Clin Nutr"},{"key":"10.1016\/j.diabet.2025.101709_bib0062","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.3390\/nu11122971","article-title":"Mediterranean diet and NAFLD: what we know and questions that still need to be answered","volume":"11","author":"Plaz Torres","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.diabet.2025.101709_bib0063","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13659","article-title":"Is there an \u201cideal\u201d diet for patients with NAFLD?","volume":"52","author":"Pugliese","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.diabet.2025.101709_bib0064","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2025.101709_bib0065","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: a major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0066","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jama.2018.20579","article-title":"Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial","volume":"321","author":"Schwimmer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2025.101709_bib0067","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ajcn\/nqaa332","article-title":"Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial","volume":"113","author":"Simons","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.diabet.2025.101709_bib0068","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0069","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.clnu.2018.11.030","article-title":"A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease","volume":"38","author":"Chen","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.diabet.2025.101709_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.08.071","article-title":"The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies","volume":"20","author":"Hayat","year":"2021","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0071","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1007\/s00125-014-3235-7","article-title":"Changes in coffee intake and subsequent risk of type 2 diabetes: three large cohorts of US men and women","volume":"57","author":"Bhupathiraju","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101709_bib0072","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2025.101709_bib0073","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.metabol.2016.12.006","article-title":"Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"68","author":"Katsagoni","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.diabet.2025.101709_bib0074","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1210\/jc.2004-1959","article-title":"Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients","volume":"90","author":"Tamura","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101709_bib0075","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc10-0856","article-title":"Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes","volume":"33","author":"Lazo","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0076","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/metabo13030330","article-title":"Therapeutic physical exercise programs in the context of NASH cirrhosis and liver transplantation: a systematic review","volume":"13","author":"Farrugia","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.diabet.2025.101709_bib0077","doi-asserted-by":"crossref","first-page":"e0108","DOI":"10.1097\/HC9.0000000000000108","article-title":"American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease","volume":"7","author":"Stine","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.diabet.2025.101709_bib0078","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.diabet.2025.101709_bib0079","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0080","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.cgh.2021.01.023","article-title":"Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort","volume":"20","author":"Malespin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0081","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/HEP.0000000000000456","article-title":"Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis","volume":"80","author":"Mallet","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0082","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0262","article-title":"Analysis of severe hypoglycemia among adults with type 2 diabetes and nonalcoholic fatty liver disease","volume":"5","author":"Lee","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2025.101709_bib0083","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5604\/01.3001.0010.0284","article-title":"Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis","volume":"16","author":"Said","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0084","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cgh.2020.04.083","article-title":"Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis-related, child-pugh a cirrhosis","volume":"19","author":"Vilar-Gomez","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0085","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/apt.17371","article-title":"Meta-analysis: chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin","volume":"57","author":"Zeng","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diabet.2025.101709_bib0086","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabet.2025.101709_bib0087","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.diabet.2025.101709_bib0088","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.25646","article-title":"Diabetes and hepatocellular cancer risk: not only a matter of hyperglycemia","volume":"55","author":"Marchesini","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0089","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jdi.12888","article-title":"Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial","volume":"10","author":"Feng","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabet.2025.101709_bib0090","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101709_bib0091","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0093","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2025.101709_bib0094","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/hep.30670","article-title":"Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"69","author":"Cusi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0095","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0096","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2337\/dc14-2548","article-title":"Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial","volume":"38","author":"Tang","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0097","doi-asserted-by":"crossref","first-page":"E829","DOI":"10.1152\/ajpendo.00133.2006","article-title":"Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes","volume":"292","author":"Juurinen","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101709_bib0098","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0099","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabet.2025.101709_bib0100","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101709_bib0101","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2337\/dc20-2887","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2 diabetes: a randomized, double-blind crossover trial","volume":"44","author":"Op den Kamp","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0102","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101709_bib0103","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.diabet.2025.101709_bib0104","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.diabet.2025.101709_bib0106","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2025.101709_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2025.06.001","article-title":"Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD","author":"Shi","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0108","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s12876-023-03085-8","article-title":"Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes and cirrhosis","volume":"23","author":"Huynh","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.diabet.2025.101709_bib0109","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","article-title":"Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease","volume":"73","author":"Mao","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.diabet.2025.101709_bib0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","article-title":"Thiazolidinediones and ppar\u03b3 agonists: time for a reassessment","volume":"23","author":"Cariou","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101709_bib0111","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0112","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diabet.2025.101709_bib0113","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2025.101709_bib0115","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabet.2025.101709_bib0116","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0117","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0118","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0119","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","author":"Jara","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0121","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0122","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-8587(17)30109-2","article-title":"Semaglutide, lipid-lowering drugs, and NAFLD","volume":"5","author":"Katsiki","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101709_bib0123","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.diabet.2025.101709_bib0124","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0125","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/dom.13186","article-title":"Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment","volume":"20","author":"Jensen","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101709_bib0126","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/apt.17925","article-title":"Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes","volume":"59","author":"Elsaid","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diabet.2025.101709_bib0127","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0128","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/gutjnl-2024-332687","article-title":"Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease","volume":"74","author":"Bea","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.diabet.2025.101709_bib0129","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101709_bib0131","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0132","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.2337\/db18-0068","article-title":"Hepatic glucagon receptor signaling enhances insulin-stimulated glucose disposal in rodents","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2025.101709_bib0133","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1038\/s41598-022-10577-2","article-title":"Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis","volume":"12","author":"Nestor","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabet.2025.101709_bib0134","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101709_bib0135","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.cgh.2023.03.041","article-title":"Clinical trial landscape in NASH","volume":"21","author":"Harrison","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0136","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0137","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2025.101709_bib0138","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101709_bib0139","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2025.101709_bib0141","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabet.2025.101709_bib0142","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.32358","article-title":"Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery","volume":"76","author":"Pais","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0143","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.cgh.2008.08.012","article-title":"Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"6","author":"Mummadi","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0144","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0145","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1210\/clinem\/dgad390","article-title":"Changes in hepatic fat content by CT 1 year after sleeve gastrectomy in adolescents and young adults with obesity","volume":"108","author":"L\u00f3pez L\u00f3pez","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101709_bib0146","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2025.101709_bib0147","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1001\/jama.2018.14619","article-title":"Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity","volume":"320","author":"Fisher","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2025.101709_bib0148","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2025.101709_bib0149","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7188","article-title":"Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity","volume":"6","author":"Krishnan","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2025.101709_bib0150","article-title":"Resolution of metabolic dysfunction-associated steatohepatitis with no worsening of fibrosis after bariatric surgery improves 15-year survival: a prospective cohort study","author":"Lassailly","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0151","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060495","article-title":"Long-term effect of bariatric surgery on liver enzymes in the Swedish obese subjects (SOS) study","volume":"8","author":"Burza","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2025.101709_bib0152","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2337\/diaspect.25.4.200","article-title":"Comparison of bariatric surgical procedures for diabetes remission: efficacy and mechanisms","volume":"25","author":"Vetter","year":"2012","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.diabet.2025.101709_bib0153","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jhep.2023.05.012","article-title":"Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis","volume":"79","author":"Lalloyer","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0154","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1007\/s11695-021-05412-y","article-title":"Gastric bypass compared with sleeve gastrectomy for nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"31","author":"de Brito","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.diabet.2025.101709_bib0155","doi-asserted-by":"crossref","first-page":"986","DOI":"10.14218\/JCTH.2021.00448","article-title":"Endoscopic bariatric and metabolic therapies for liver disease: mechanisms, benefits, and associated risks","volume":"10","author":"Ren","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0156","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0157","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep.24418","article-title":"Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis","volume":"54","author":"Berzigotti","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.diabet.2025.101709_bib0158","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.soard.2020.11.004","article-title":"Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis","volume":"17","author":"Agarwal","year":"2021","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101709_bib0159","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cgh.2011.07.007","article-title":"Increased perioperative mortality following bariatric surgery among patients with cirrhosis","volume":"9","author":"Mosko","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0160","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.cgh.2020.10.034","article-title":"AGA clinical practice update on bariatric surgery in cirrhosis: expert review","volume":"19","author":"Patton","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101709_bib0161","article-title":"Transjugular intrahepatic portosystemic shunt (TIPS): a bridge to bariatric surgery in morbidly obese patients with cirrhosis and clinically significant portal hypertension","author":"Pais","year":"2024","journal-title":"Obes Surg"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236362500103X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236362500103X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:25:26Z","timestamp":1763684726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S126236362500103X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":159,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S126236362500103X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101709","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of patients with type 2 diabetes and MASLD: An overview and joint statement","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101709"}}